{
    "clinical_study": {
        "@rank": "146162", 
        "arm_group": [
            {
                "arm_group_label": "Treatment group", 
                "description": "Subjects in this group will received Endoclot treatment immediately after EMR."
            }, 
            {
                "arm_group_label": "Control group", 
                "description": "Subjects in this group will not received any hemostasis treatment after EMR."
            }
        ], 
        "brief_summary": {
            "textblock": "Endoscopic mucosal resection (EMR) has been widely used as a diagnostic and treatment\n      techniques of gastrointestinal small lesions. Postoperative rebleeding is one of the common\n      complication following EMR. Several endoscopic hemostasis methods are currently in use.\n      EndoClot\u00ae absorbable polysaccharide hemostat (PAPH) as a new hemostasis material was\n      previously used for surgical hemostasis, but the therapeutic effect and safety in endoscopic\n      application remains unknown. This study has been designed to observe the effect of\n      rebleeding prevention after EMR."
        }, 
        "brief_title": "EndoClot for Preventing Rebleeding After Endoscopic Mucosal Resection (EMR)", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Endoscopic Hemostasis", 
            "Colonic Polyps"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colonic Polyps", 
                "Polyps"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  consecutive cases of colorectal polyps and submucosal lesions with anticipated\n             complete removal endoscopically by EMR.\n\n        Exclusion Criteria:\n\n          -  severe cardiovascular diseases, liver and kidney dysfunction;\n\n          -  platelet and coagulation dysfunction (PLT < 50*109/L, INR > 2);\n\n          -  cases that have taken anticoagulant drugs or non-steroidal anti-inflammatory drugs\n             within 1 month before the procedure;\n\n          -  cases unavailable for follow-up."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Consecutive cases of colorectal mucosal and submucosal lesions with intented EMR treatment"
            }
        }, 
        "enrollment": {
            "#text": "164", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735786", 
            "org_study_id": "20121125"
        }, 
        "intervention": {
            "arm_group_label": "Treatment group", 
            "description": "EndoClot hemostat is applied immediately after EMR to achieve hemostasis.", 
            "intervention_name": "EndoClot", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": "Hemostatics"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Endoscopic Hemostasis", 
            "EndoClot Absorbable Polysaccharide Hemostat", 
            "Colonic Polyps"
        ], 
        "lastchanged_date": "November 27, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Xi'an", 
                    "country": "China", 
                    "state": "Shanxi", 
                    "zip": "710032"
                }, 
                "name": "Xijing Hospital of Digestive Diseases"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "EndoClotTM Absorbable Polysaccharide Hemostat for Preventing Rbleeding After Endoscopic Mucosal Resection (EMR)", 
        "overall_official": {
            "affiliation": "Xijing Hospital of Digestive Diseases, Xi'an, Shaanxi, China  710032", 
            "last_name": "Zhiguo Liu, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China:Xijing Hospital of Digestive Diseases", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Rebleeding rate up to 1 week was obtained by clinical manifestations such as melana; decreased hemoglobin > 20g/L; hemodynamic instability or active bleeding from mucosal defect under endoscope.", 
            "measure": "Rebleeding rate after EMR procedure", 
            "safety_issue": "No", 
            "time_frame": "up to 1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735786"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Xijing Hospital of Digestive Diseases", 
            "investigator_full_name": "Zhiguo Liu", 
            "investigator_title": "Associated Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Colonoscopy will be repeated 1 month after EMR procedure to observe if application of Endoclot will delay the musosal healing.", 
                "measure": "Mucosal healing after EMR", 
                "safety_issue": "No", 
                "time_frame": "up to 1 month"
            }, 
            {
                "description": "Gastrointestinal tract obstruction has been previously reported as a possible adverse effect of hemostats, therefore it was observed in the current study.", 
                "measure": "gastrointestinal tract obstruction", 
                "safety_issue": "No", 
                "time_frame": "up to 1 month"
            }
        ], 
        "source": "Xijing Hospital of Digestive Diseases", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xijing Hospital of Digestive Diseases", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}